A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer.

Br J Cancer · 2012 · PMC3305956 · PMID 22333599

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.0660

boldest claim

The sentences

borderline significantP =0.060so close (0.05 < p ≤ 0.1)

However, in patients with stage III-IV disease ( n =236), high SATB2 expression was associated with a significantly prolonged CSS (HR=0.55, 95% CI 0.33–0.93, P =0.025) and OS (HR=0.60, 95% CI 0.37–0.98, P =0.041) and in multivariable analysis, this association remained significant for CSS (HR=0.52, 95% CI 0.28–0.95, P =0.034) and borderline significant for OS (HR=0.60, 95% CI 0.35–1.03, P =0.060) ( Table 3 ).

also in 11,409 other papers

did not reach statistical significanceP =0.066so close (0.05 < p ≤ 0.1)

SATB2 expression was lower in colon cancer with 101 out of 321 (31.5%) negative tumours compared with rectal cancer, where 46 out of 193 (23.8%) tumours were SATB2 negative , although this difference did not reach statistical significance ( R =0.081, P =0.066).

also in 111,027 other papers

highly significantno p-value reported

A highly significant inverse correlation was seen between SATB2 expression and MSI tumours in the full cohort and in colon cancer ( Table 1 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.